Why this is a genuine decision, not a default

Being told you have a focal cartilage defect — and that surgery is one of your options — puts you at a genuine crossroads. For most of the past two decades, an operation was effectively the default once a defect reached a certain size. Injectable scaffold technology has changed that calculus: there is now a non-surgical lane that covers a comparable range of defect sizes, and patients are rightly asking whether it can do the same job.

The honest answer is that neither pathway is automatically better. The choice turns on several factors working in combination: how large the defect is, how deep it runs, the condition of the surrounding cartilage, your general fitness, and how much recovery disruption you can realistically absorb. Change any one of those variables and the balance can shift.

What follows maps the published evidence for each option — injectable collagen scaffold on one side, the main surgical techniques on the other — so that when you sit down with a specialist, you arrive with realistic expectations rather than assumptions.

The anatomy of a focal defect — and who qualifies for repair

Think of a focal cartilage defect as a pothole in an otherwise intact road surface. The damage has defined edges; healthy cartilage surrounds it on all sides. That surrounding tissue acts as a structural wall — it is what allows any repair material, whether injected scaffold or surgical graft, to be contained, supported, and integrated rather than simply washing away. Diffuse osteoarthritis, by contrast, resembles cracked tarmac across the whole surface: no healthy border remains, and there is nothing for a focal repair to build against.

Defect size is one of the first triage criteria clinicians use. Published evidence maps different techniques across a rough size spectrum: smaller defects (broadly under two to four square centimetres) can sometimes be addressed by bone-marrow stimulation techniques, while moderate-to-large focal defects push into territory where cell-based or scaffold-based options may be more appropriate. Grade and depth matter too — classification systems such as ICRS grade the lesion from superficial surface damage through to full-thickness loss exposing subchondral bone; deeper lesions introduce additional considerations around bone health that influence technique choice.

Beyond size and grade, several other factors determine whether any focal repair pathway is appropriate: lower-limb alignment (a malaligned knee places uneven load on a repair site), body mass index, ligament stability, and a patient's activity goals and expectations. No single factor is decisive on its own.

Because these variables interact, imaging alone is not sufficient to confirm eligibility. A clinical assessment that combines examination findings, load-bearing X-rays, and MRI is generally needed before any pathway — surgical or injectable — can be recommended.

What ChondroFiller does inside the defect

The material itself explains why ChondroFiller belongs in a different category from other injectables. It is a liquid Type I collagen derived from rat-tail tendon — the same structural protein found in the body's own connective tissue. What makes it clinically distinct is the manufacturing step: the collagen is extracted by a non-enzymatic, weak-acid process that preserves intact telopeptide regions. Those telopeptides are the molecular hooks that allow collagen fibres to cross-link in the way native tissue does. When the liquid is placed into a defect, it polymerises in situ — forming a three-dimensional scaffold that conforms to the lesion geometry rather than sitting as an inert mass the joint later expels.

The delivery is an outpatient procedure: the product is placed under ultrasound guidance directly into the defect site, with no theatre admission and no general anaesthetic required.

Once in place, the scaffold is designed to give the body's own repair cells somewhere to migrate, anchor, and mature. Published MOCART imaging data support this model: scores in European knee studies progressed from around 65 points at four weeks to over 80 at one year, suggesting ongoing biological integration rather than a static volume-fill effect.

The distinction from other injectable options matters clinically. Hyaluronic acid acts principally as a lubricant — it supplements synovial fluid and is cleared within weeks, providing no lasting structural change to the defect itself. Polyacrylamide hydrogels are permanent but non-biological: the joint cannot integrate or remodel them. ChondroFiller, by contrast, is designed to be colonised and incorporated into the repair site. Published data describe the outcome as hyaline-like structural repair rather than confirmed regrowth of native cartilage — an important distinction that should inform expectations before any treatment decision is made.

The surgical alternatives and what they require

Surgery for focal cartilage defects is a well-established clinical pathway, and for some patients it remains the most appropriate route — particularly where defect size, depth, or associated bony injury makes a scaffold-injection approach insufficient.

Microfracture

The most commonly performed cartilage procedure worldwide, microfracture involves making small perforations in the subchondral bone to allow marrow-derived cells to fill the lesion. The technique is arthroscopic, relatively straightforward, and has decades of follow-up data. Its limitation is biological: the tissue that fills the defect is predominantly fibrocartilage — mechanically weaker than the hyaline cartilage it replaces. Published evidence also suggests an upper size boundary of roughly two to four square centimetres, beyond which outcomes tend to decline, and some series report a gradual deterioration in results over time rather than durable repair.

ACI and MACI

Autologous chondrocyte implantation (ACI) and its matrix-supported evolution (MACI) achieve hyaline-like tissue repair, and clinical trials — including the SUMMIT trial at five years — show meaningful improvements in pain and function scores for defects at or above three square centimetres. The procedural commitment, however, is substantial: two separate hospital admissions, general anaesthesia on each occasion, an interim laboratory cell-culture step lasting several weeks, and a protected rehabilitation programme measured in months. Published series also report notable complication and reoperation rates, though these vary by technique and follow-up period.

Osteochondral transfer (OAT / mosaicplasty)

This technique transplants one or more cylindrical plugs of bone and cartilage from a low-load donor area of the same joint into the defect. It works best for smaller, well-contained lesions and can produce good structural outcomes, though it introduces a donor-site consideration: harvesting tissue from elsewhere in the knee creates its own, generally minor, area of damage.

All three surgical approaches require theatre access, anaesthesia, and formal postoperative rehabilitation — a meaningful time and lifestyle commitment, particularly for working-age patients balancing employment and family responsibilities. Whether that commitment is warranted depends on individual defect characteristics and patient circumstances, which a specialist assessment will determine.

How the outcomes compare across pathways

Putting numbers alongside each pathway reveals a more nuanced picture than a simple surgery-versus-injection framing suggests.

Published series across four knee studies report a mean IKDC improvement of approximately 30 points for ChondroFiller — a gain that exceeds the minimum clinically important difference of 16.7 points and, in one prospective post-market study by Jerosch and colleagues, was sustained at the three-year mark. MACI clinical trials, including the SUMMIT trial, report IKDC and KOOS gains in a broadly comparable range for similar defect sizes. In other words, the functional outcome headline looks similar between the two pathways — but the route to that outcome differs considerably. ACI and MACI require two separate admissions and an interim cell-culture interval; the injection pathway is a single outpatient appointment.

Defect size coverage is a meaningful differentiator at the selection stage. Published ChondroFiller data describe use in defects up to approximately six square centimetres in a single session. Microfracture evidence, as the previous section noted, tends to weaken above two to four square centimetres — the SUMMIT trial's five-year data showed MACI producing significantly better scores than microfracture for defects at or above three square centimetres, positioning the injection scaffold pathway as potentially relevant precisely where microfracture is least reliable.

Tissue-quality data from imaging studies suggest hyaline-like structural repair for both ChondroFiller and MACI, though the evidence methodologies differ and direct imaging comparisons have not been conducted.

A critical limitation must be stated plainly. No published randomised controlled trial has directly compared ChondroFiller injection against any surgical cartilage technique. Existing ChondroFiller data are largely single-arm cohort studies, some with manufacturer involvement in their design or reporting. Every comparison drawn here is therefore indirect — useful for understanding the landscape, but not a substitute for a prospective head-to-head evaluation that does not yet exist. Individual suitability depends on factors that only a specialist assessment can weigh.

When a single injection may not be the full answer

The scaffold injection pathway covers a wide range of focal defects, but some clinical situations call for a different approach — either an enhanced non-surgical protocol or, in a minority of cases, surgery as the appropriate first step.

A single-session cell-augmented option

For higher-grade focal lesions where additional biological support may be beneficial, early published data support combining a collagen scaffold with autologous cartilage-derived cells and platelet-rich fibrin — all delivered in a single outpatient, non-arthroscopic session. The concept compresses what was previously a two-stage cell-therapy process (harvest, laboratory culture, reimplantation) into one appointment, without theatre admission or general anaesthesia. A published case series by Weninger and colleagues (2025) reported outcomes for this combined approach in Grade IV knee lesions, offering initial evidence that the combination can work in practice. No randomised controlled trial has yet evaluated the full protocol, however. Early published data suggest a promising emerging pathway; it should not yet be understood as an established standard of care.

When focal repair approaches do not apply

Not every knee is a candidate for any form of focal repair. As outlined above, diffuse cartilage loss removes the healthy surrounding margins that all focal repair techniques — injectable or surgical — require; where loss is widespread, the clinical question changes entirely. Beyond diffuse disease, complex structural problems — significant lower-limb malalignment, combined ligament instability, or substantial subchondral bone pathology — may require surgical correction as a necessary first step before any cartilage repair can be meaningfully attempted.

Which of these situations applies to a given knee is something only a clinical and imaging assessment can determine. Patients wanting to clarify their individual options can begin with a structured eligibility assessment.